Quick Answer
Verrica Pharmaceuticals Inc. reported Stockholders Equity of $24.74 million for the year ending 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +350.9% in Stockholders Equity from 2024 to 2025.
- This data is from Verrica Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$8.75 million | Q2 2018: $101.59 million | Q3 2018: $96.35 million | Q1 2019: $82.76 million | Q2 2019: $76.85 million | Q3 2019: $71.65 million | Q1 2020: $56.61 million | Q2 2020: $48.46 million | Q3 2020: $39.18 million | Q1 2021: $61.81 million | Q2 2021: $52.16 million | Q3 2021: $40.85 million | Q1 2022: $25.42 million | Q2 2022: $16.33 million | Q3 2022: $44.77 million | Q1 2023: $64.85 million | Q2 2023: $55.40 million | Q3 2023: $42.30 million | Q1 2024: $1.51 million | Q2 2024: -$13.30 million | Q3 2024: -$34.05 million | Q1 2025: -$18.58 million | Q2 2025: -$17.48 million | Q3 2025: -$17.04 million.
- Over the full 10 years of available data (2016 to 2025), Verrica Pharmaceuticals Inc.'s Stockholders Equity has grown by 1,028.8%.
- Historical annual values: Fiscal year 2025: $24.74 million | Fiscal year 2024: -$9.86 million | Fiscal year 2023: $19.76 million | Fiscal year 2022: $40.03 million | Fiscal year 2021: $32.61 million | Fiscal year 2020: $32.99 million | Fiscal year 2019: $65.02 million | Fiscal year 2018: $89.43 million | Fiscal year 2017: -$7.04 million | Fiscal year 2016: -$2.66 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: